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Glycogenosis type II (Pompe disease) is a rare autosomal recessive genetic disorder caused by mutations in the
gene encoding the lysosomal enzyme acid α-glucosidase. The classic form is characterized by severe cardiac
involvement, generalized hypotonia and exitus early in life. Presenting symptoms and signs of the disease may be
neglected or underestimated, thus delaying the diagnosis. Respiratory manifestations mainly occur because of
respiratory muscle weakness. However, additional mechanisms can favor the development of pulmonary
complications that result in fatal respiratory failure. We herein describe a case of an infant with glycogenosis type II
presenting with hepatomegaly and hypertransaminasemia, who rapidly developed fatal lung disease.
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Glycogenosis type II, a rare autosomal recessive lysosomal
storage disorder (LSD), is caused by mutations in the acid
α-glucosidase (GAA) gene encoding for the lysosomal
hydrolase GAA that is involved in the breakdown of
glycogen into glucose [1].
Although the deficiency of GAA is generalized, muscles
appear to be particularly vulnerable to glycogen storage.
The clinical manifestations of the disease are thus mainly
related to the involvement of skeletal muscles and heart,
and are characterized by progressive muscle hypotonia,
motor impairment, respiratory failure, and, exclusively in
the classic infantile variant, severe hypertrophic cardio-
myopathy [1]. The phenotypic spectrum of the disease is
broad and ranges from early-onset severe phenotypes to
late-onset attenuated clinical forms [1]. The infantile form
(Pompe disease) has a rapidly progressive course and exi-
tus occurs usually within two years of age [2]. Infants with
Pompe disease present in the first few months of life with
feeding problems, poor weight gain, respiratory difficulties
frequently complicated by pulmonary infections, or
delayed motor milestones. Laboratory findings include
elevated levels of serum creatine kinase (CK), aspar-
tate aminotransferase (AST), and lactate dehydrogenase
(LDH) [2].* Correspondence: santamar@unina.it
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distribution, and reproduction in any mediumBecause most LSD are systemic, virtually all organs
may be involved to a greater or lesser degree. Several
LSD have airways disease as part of the clinical picture,
yet at presentation or as late-onset features [3-6].
Here we report the case of a 6 months old infant with
Pompe disease who initially was referred to us for a suspect
of liver disease, and rapidly developed a fatal pulmonary
complication.Case presentation
The child was a full-term girl, born to unrelated healthy
parents after an uneventful pregnancy. Parents reported
regular growth and denied any clinical problems during
the first months of life. In September 2002, at 6 months
of age, she was referred to our Department for further
diagnostic work-up because of overt hepatomegaly and
occasional finding of hypertransaminasemia at routine
blood analysis requested for intercurrent upper airways
infection. At admission weight and length were appro-
priate for the age (25th and 50th percentile, respec-
tively). On physical examination macroglossia and severe
generalized muscle hypotonia were evident. She had no
evidence of jaundice. The heart rate was 150 beats per
minute with gallop rhythm and no added murmurs. Pe-
ripheral pulses were normal. Blood pressure was 100/70
mmHg. Respiratory rate was 30 breaths per minute, and
the transcutaneous oxygen saturation (SaO2) at room airtral Ltd. This is an Open Access article distributed under the terms of the
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of air without additional pathological sounds. The abdo-
men was not distended. The liver edge was palpable 4
cm below the costal margin with smooth surface and
increased consistency. There was no splenomegaly.
The patient underwent blood routine biochemistry and
complete cell count. Laboratory findings were all unre-
markable, with the exception of hypertransaminasemia
[AST = 444 U·l-1, alanine aminotransferase (ALT) = 315
U·l-1], increased levels of alkaline phosphatase (1428 U·l-1),
LDH (3925 U·l-1), CK (1373 U·l-1) and aldolase (26.6 U·l-
1). Hepatobiliary ultrasound showed a liver of larger size
for the age, with no evidence of focal lesions. At chest
x-ray diffuse hyperinflation in the absence of any paren-
chymal consolidation, and cardiomegaly were evident
(Figure 1). The electrocardiogram showed a short P-R
interval, with signs of left ventricular pressure-overload.
The echocardiography revealed the dilation of the left ven-
tricular and atrial cavity, with thickening of the septum
and of the walls of the left ventricle, which showed diffuse
and severe hypokinesia. Therefore, treatment with digi-
talis, diuretics and vasodilators was started.
The clinical presentation (cardiomegaly, severe gene-
ralized muscular hypotonia, hepatomegaly), and the in-
crease in serum enzymes levels (AST, ALT, CK, aldolase,
LDH) raised the diagnostic suspicion towards glycogen
storage disease type II. The reduction in acid α-glucosi-
dase activity, measured in cultured fibroblasts (1.6 nmol/
mg/h, normal values 64.4 ± 22.9), and the molecular
analysis of the GAA gene that showed a homozygous
mutation (C1124G> T/C1124G> T) confirmed the diag-
nosis of Pompe disease.
In the following weeks the clinical course was characte-
rized by recurrent respiratory upper and lower airways
infections, that required monthly treatment with systemic
antibiotics, and progressive dyspnoea and tachypnoea. AtFigure 1 Chest x-ray showing widespread lung hyperinflation
and severe cardiomegaly.9 months a chest high resolution computed tomography
(HRCT) performed because of lower respiratory tract in-
fection unresponsive to prolonged antibiotics therapy,
revealed massive atelectasis of the left lung with diffuse
air-trapping (Figure 2). A significant increase in heart vo-
lume was also evident, and this finding appeared consist-
ent with a possible compressive effect of the massive
cardiomegaly on the left main bronchus. In the following
weeks the SaO2 at room air progressively decreased, and
O2 supplementation, combined with a daily program of
chest physiotherapy, was started. At the age of 10 months,
after a further episode of pneumonia, the patient deve-
loped acute respiratory failure with severe hypoxemia and
hypercapnia (PaO2 36 mmHg, PaCO2 68 mmHg) that
required the admission to the Paediatric Intensive Care
Unit. Despite mechanical ventilation, her condition pro-
gressively worsened, and she eventually died. The parents
did not authorise an autopsy.
Discussion
The most severe form of Pompe disease is typically diag-
nosed in infants between 3 and 5 months of age during
the assessment of a respiratory infection, cardiomegaly, or
hypotonia [2]. However, symptoms and signs of the dis-
ease might be neglected or underestimated, this resulting
in delayed referral to specialized centers for diagnostic
confirmation. In the described case, the hospital admission
was required because of suspected liver disease, and the
clinical picture of generalized hypotonia was not reported
as the main clinical problem of the baby.
Severe hypotonia of the skeletal muscles associated with
breathing (diaphragm, intercostal and accessory muscles)
is described in Pompe disease, this resulting in inability to
generate normal levels of pressure and flow in the airways
during inspiration and expiration [7-9]. These events sig-
nificantly impair the removal of secretions from theFigure 2 High-resolution computed tomography of the lung,
showing massive atelectasis of the left lung with signs of
intraparenchymal air trapping.
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infections that affect morbidity and mortality of patients
[2]. Additional mechanisms, such as the aspiration of
infected secretions and/or of food in the airways, can
eventually result in the development of lung lesions in-
cluding segmental to lobar atelectasis and bronchiectasis.
A recent study of 13 children with Pompe disease high-
lighted the central role of videofluoroscopy in detecting
swallowing disturbances that were evident in most of the
study population [10]. In our patient, the association of
massive cardiomegaly with respiratory muscle weakness
likely explains the development of progressive lung dam-
age and irreversible respiratory failure.
During the past two decades, impressive progress has
been made in the treatment of Pompe disease [11]. In-
deed, despite enzyme replacement therapy is currently the
only clinically approved treatment, different therapeutic
approaches are under investigation, including enzyme en-
hancement therapy by pharmacological chaperones and
gene therapy [1,11,12]. Furthermore, substrate reduction
therapy has been proved to significantly improve struc-
tural, metabolic and functional defects in a murine model
of glycogenosis type II, offering a new perspective for the
future treatment of this condition [13].
Rarity of the disease and variations in clinical presen-
tation often result in considerable delay in the diagnosis
of Pompe disease, and a severely impaired health status
already at time of diagnosis has been reported [14].
These observations, associated with the better clinical
outcomes achieved when enzyme replacement therapy is
started early, highlight the importance of timely detec-
tion of Pompe disease [14]. Particularly, since methods
for dried bloodspot screening are currently being ex-
plored, neonatal screening represents the most promis-
ing option to enable earlier diagnosis, and a recent study
has shown that nationwide testing of GAA-activity in
dried bloodspots substantially reduced the diagnostic
delay for infants with classic infantile Pompe disease
[15]. Nevertheless, the impossibility of currently available
screening techniques to discriminate between classic in-
fantile Pompe disease and less progressive variants of
the condition raises a number of ethical, legal and social
considerations that warrant further research to explore
the potential of neonatal screening of this disease.
In patients with Pompe disease not treated progressive
respiratory failure is an important cause of morbidity
and mortality [2]. The age at death depends on the
speed of progression of the symptoms and the extent of
muscle involvement [2]. In natural history studies of
infants, the gap between diagnosis and ventilator use or
death was 1 to 2 months, and nearly all cases died by
the age of 18 months [16].
Unfortunately, enzyme replacement therapy has been
available in Italy only from 2006, and at the time thepatient was assisted at our Department (2002) we could
not prescribe it. Despite not all patients benefit equally
from this therapeutic approach and, particularly, cross-
reactive immunologic material-negative subjects have
showed poor clinical response [17], favorable outcomes
with early intravenous enzyme replacement therapy have
been reported [16,18-21]. In particular, treated patients
have lower risk of undergoing mechanical ventilation,
with a 100% survival rate at 18-month [18]. Finally, the
benefits of long term therapy appear evident even at the
age of 36 months [19].
Conclusions
Respiratory manifestations seriously complicate the course
of Pompe disease through several mechanisms (genera-
lized muscle hypotonia, aspiration pneumonia, develop-
ment of pulmonary atelectasis) and are often the cause of
premature death. Early diagnosis is crucial to improve the
final outcome of the disorder. Therefore, recognition of
even subtle symptoms and signs is strongly recommended
since early treatment significantly improves patients’ sur-
vival and may definitely change the natural history of the
disorder. Finally, since glycogen storage disorders are mul-
tisystemic, the individual management should be handled
by a multidisciplinary team of specialists including pedia-
tricians expert in inborn errors of metabolism, pulmonolo-
gists, cardiologists, radiologists and respiratory therapists.
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